MedTrace Logo

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Participants

NCT01887535 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2014-01-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple-ascending dose JNJ-54861911 which is currently being developed for the treatment of Alzheimer's disease.

Conditions

  • Healthy

Interventions

DRUG

JNJ-54861911 3 mg

JNJ-54861911 3 mg will be administered as an oral suspension formulation.

DRUG

JNJ-54861911 10 mg

JNJ-54861911 10 mg will be administered as an oral suspension formulation.

DRUG

JNJ-54861911 30 mg

JNJ-54861911 30 mg will be administered as an oral suspension formulation.

DRUG

JNJ-54861911 80 mg

JNJ-54861911 80 mg will be administered as an oral suspension formulation.

DRUG

JNJ-54861911 25 mg

JNJ-54861911 25 mg will be administered as a solid dose formulation.

DRUG

Placebo

Matching placebo will be administered as an oral suspension formulation.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01887535 on ClinicalTrials.gov